Botulinum toxin type A

Botulinum toxin type A is the serotype behind many of the most visible botulinum toxin products. It appears across therapeutic neurology, rehabilitation, sweating disorders, selected pain-related treatment contexts, glandular uses, and aesthetic facial treatment. It is still a biologic category rather than a single medicine.

Product Ecosystem

Type A has the broadest current product footprint among medically used botulinum toxin serotypes. Product names connect to different manufacturers, regional labels, formulations, and comparison limits.

Product	Manufacturer / company context	Product context
Botox	AbbVie / Allergan	A major reference brand across therapeutic and aesthetic discussions, with product-specific labels and unit language.
Dysport	Ipsen product context; Galderma aesthetic commercialization	Often compared with Botox because both are visible type A products, but their units are not interchangeable.
Xeomin	Merz Pharma	Often discussed through formulation and handling differences within the type A category.
Jeuveau	Daewoong Pharmaceutical manufacturing; Evolus commercialization	A Korea-origin type A product with U.S. aesthetic-market visibility.
Daxxify	Revance / Crown Laboratories	A U.S.-approved type A product with peptide-formulated product identity and aesthetic plus cervical dystonia label context.
Letybo	Hugel	A Korea-origin type A product with U.S. glabellar-line approval and broader market-specific naming context.

Galderma also markets Relfydess, or relabotulinumtoxinA, internationally and is pursuing U.S. approval. FDA acceptance of its BLA resubmission for review, announced on February 2, 2026, is not U.S. approval (Galderma 🔗).

Those products can share a serotype while remaining distinct regulated medicines. Shared type A biology does not create a universal conversion ratio, a common approval profile, or a general ranking.

Mechanism Context

Type A reduces acetylcholine release by acting on SNAP-25, a SNARE protein involved in signal release from the nerve ending. Acetylcholine is a chemical messenger used by cholinergic nerves to communicate with muscles and glands. When release is reduced in a selected target pattern, muscle contraction or glandular activity can temporarily decrease.

The broader sequence is covered in botulinum toxin mechanism of action. For comparison with type B, see botulinum toxin type A vs type B.

Label And Clinical Footprint

Type A products have a broad clinical and aesthetic footprint, but that footprint is not a single shared approval profile. A product may have strong evidence for one use, a different label in another region, and common discussion elsewhere that does not equal approval.

This distinction is especially important in comparison content. “Type A” can identify a mechanism family, but it does not answer which indications are approved, which warnings apply, how units are defined, or whether a product is available in a particular market.

Unit And Comparison Limits

Type A products use product-specific potency units. A larger headline unit number does not automatically mean a stronger, wider-spreading, longer-lasting, or safer treatment. Unit interpretation belongs inside product labeling, clinical evidence, anatomy, and treatment plan.

This issue shapes how readers should approach diffusion claims, immunogenicity discussion, and brand comparisons. Type A is a useful category, but product-specific evidence carries the interpretive weight.